Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and dose-response relationship of
N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects
administered MOA-728 who have chronic pain that is not due to cancer, and who have
opioid-induced bowel dysfunction (OIBD).
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.